Global escalation in carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter baumannii infections: Serious threat to human health from the pink corner

被引:3
|
作者
Sannathimmappa, Mohan [1 ,2 ]
机构
[1] Natl Univ Sci & Technol, Dept Microbiol Coll Med & Hlth Sci, Sohar, Oman
[2] Natl Univ Sci & Technol, Dept Microbiol Coll Med & Hlth Sci, POB 391,Al Tareef, Sohar 321, Oman
来源
关键词
Acinetobacter; antimicrobial stewardship; carbapenemases; Enterobacterales; healthcare-associated infections; plasmids; CULTURE IDENTIFICATION PANEL; KLEBSIELLA-PNEUMONIAE; RAPID DETECTION; MOLECULAR EPIDEMIOLOGY; EMERGING CARBAPENEMASES; FILMARRAY BLOOD; BETA-LACTAMASE; OXA-48; DETERMINANTS; BACTEREMIA;
D O I
10.4103/bbrj.bbrj_366_22
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Rise in carbapenem-resistant Gram-negative bacterial infections, especially among immunocompromised patients in healthcare settings is an imminent threat as they are difficult to treat and result in a prolonged length of hospital stay, frequent treatment failures, increased economic burden on the patient and the nation, and a high rate of morbidity and mortality. Major carbapenemase-producing Gram-negative bacteria are carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) such as Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and others. These bacteria that contaminate health-care settings are the major causes of a wide range of hospital-associated infections including life-threatening septicemia, pneumonia, meningitis, bones and joint infections, and skin and soft-tissue infections. Carbapenems are regarded as last resort available antibiotics to treat multidrug-resistant Gram-negative bacterial infections that show resistance to most of the beta-lactam antibiotics in addition to fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole. Emergence and spread of carbapenem-resistant Gram-negative pathogens such as CRE and CRAB is a matter of serious concern because of limited treatment options and grave consequences. The World Health Organization has given level one priority to these pathogens and the United States Centers of Disease Control and Prevention considers CRE and CRAB as one of the top five most priority pathogens of public health importance. Strict control measures by the government and public is critical to prevent emergence and dissemination of these dangerous pathogens. In this article, the authors have summarized the microbiological and epidemiological perspectives of CRE and CRAB with a special focus on diagnosis, prevention, and novel promising alternative treatment strategies.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 50 条
  • [1] Treating carbapenem-resistant Acinetobacter baumannii infections
    Giannella, Maddalena
    Viale, Pierluigi
    LANCET INFECTIOUS DISEASES, 2023, 23 (09): : 994 - 995
  • [2] A global view on carbapenem-resistant Acinetobacter baumannii
    Mueller, Carina
    Reuter, Sandra
    Wille, Julia
    Xanthopoulou, Kyriaki
    Stefanik, Danuta
    Grundmann, Hajo
    Higgins, Paul G.
    Seifert, Harald
    MBIO, 2023, 14 (06)
  • [3] Global spread of carbapenem-resistant Acinetobacter baumannii
    Higgins, Paul G.
    Dammhayn, Cathrin
    Hackel, Meredith
    Seifert, Harald
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) : 233 - 238
  • [4] The Rise of Carbapenem-Resistant Acinetobacter baumannii
    Evans, Benjamin A.
    Hamouda, Ahmed
    Amyes, Sebastian G. B.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (02) : 223 - 238
  • [5] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
    Apisarnthanarak, Anucha
    Jitpokasem, Sumana
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11): : 1235 - 1237
  • [6] Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii
    Rossi, Iara
    Royer, Sabrina
    Ferreira, Melina Lorraine
    Campos, Paola Amaral
    Fuga, Bruna
    Melo, Gabriel Nogueira
    Machado, Luiz Gustavo
    Resende, Daiane Silva
    Batistao, Deivid
    Urzedo, Jane Eire
    Gontijo-Filho, Paulo P.
    Ribas, Rosineide Marques
    AMERICAN JOURNAL OF INFECTION CONTROL, 2019, 47 (12) : 1431 - 1435
  • [7] Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections
    Iovleva, Alina
    Fowler Jr, Vance G.
    Doi, Yohei
    DRUGS, 2025, 85 (01) : 21 - 40
  • [8] Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
    Zhang, Siqin
    Di, Lingfang
    Qi, Yan
    Qian, Xiang
    Wang, Siwei
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [9] Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation
    Reddy, P.
    Zembower, T. R.
    Ison, M. G.
    Baker, T. A.
    Stosor, V.
    TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (01) : 87 - 93
  • [10] Carbapenem-resistant Acinetobacter baumannii in the Republic of Belarus
    Gorbich, Yury
    Karpov, Igor
    Edelstein, Mikhail
    Martinovich, Alexey
    Kretchikova, Olga
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (03) : 201 - 202